LOS ANGELES, CA - July 6, 2026 - VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate programs and two non-BiTAC assets available for partnering.
VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. This strategic focus underscores the company's commitment to its next-generation cancer therapies.
Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its pipeline.
The BiTAC platform, a registered trademark of VERAXA Biotech GmbH, is designed to generate bispecific T-cell engagers that redirect the body’s immune system to attack cancer cells. The company's pipeline expansion into solid tumors represents a significant area of unmet medical need, as many current T-cell engagers are limited to hematologic malignancies. Success in solid tumors could broaden the therapeutic reach of this class of drugs.
For the pharmaceutical industry, VERAXA's progress signals a growing trend toward bispecific antibodies and ADCs, which are becoming key modalities in oncology. The company's ability to attract partner interest at major conventions like BIO indicates that its technology is gaining recognition. If VXA-102 reaches IND/CTA readiness, it could open doors for licensing deals or co-development agreements, potentially accelerating the path to market for a novel solid tumor therapy.
The impact on patients could be substantial if BiTAC-based therapies prove effective against solid tumors, which account for about 90% of all cancers. Current T-cell engager therapies have shown remarkable efficacy in blood cancers but have faced challenges in solid tumors due to the tumor microenvironment. VERAXA's BiTAC platform, built on scientific breakthroughs from the European Molecular Biology Laboratory, may offer innovative solutions to these challenges.
VERAXA's decision to monetize non-BiTAC assets provides a pragmatic funding pathway, reducing dilution for existing shareholders while allowing the company to focus resources on its core technology. This approach may serve as a model for other biotech firms with multiple platform assets.
Forward-looking statements in the release are subject to risks and uncertainties, including those detailed in the company's filings with the SEC. The full press release is available at https://ibn.fm/xTF5q, and the latest news can be found at https://ibn.fm/VRXA.
